Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 227 от 240

Активно (без набиране) Фаза 3

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

Начало: 20.08.2020 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +11 Seagen, a wholly owned subsidiary of Pfizer NCT04404283

Активно (без набиране) Фаза 1

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Aggressive Variant Prostate Carcinoma Castration-Resistant Prostate Carcinoma Metastatic Clear Cell Renal Cell Carcinoma Metastatic Malignant Solid Neoplasm +6

This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the body (metastatic). DS3201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving DS3201 and ipilimumab may help to control the disease.

Начало: 20.08.2020 Край: 31.12.2026 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT04388852

Активно (без набиране)

Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis

NASH - Nonalcoholic Steatohepatitis Cirrhosis, Liver

This is an open-label, randomized study comparing a monitored ketogenic diet intervention using standard ketogenic diet (SKD) and standard of care (SOC) dietary recommendations for 16 weeks. Subjects enrolled in the standard of care group will receive a voucher to Weight Watchers after study completion.

Начало: 15.08.2020 Край: 31.12.2026 Възраст: от 18 г.

United States Indiana University NCT04383951

Активно (без набиране)

Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma

Brain Neoplasm Low Grade Glioma Seizure Disorder

This study investigates how seizures can vary over time with changes in low grade gliomas and its treatments. This study may help doctors find symptoms or triggers of seizures earlier than normal, and ultimately earlier care or treatment for seizures.

Начало: 08.07.2020 Край: 30.12.2027

United States M.D. Anderson Cancer Center NCT04553757

Активно (без набиране)

Nursing Students' Brain/MS Immersive Three-Dimensional Learning Activity

Multiple Sclerosis

This study compared two educational methods. Participants were assigned to participate in a 360-degree experience or a slideshow presentation. The 360-degree video group included a brain and MS program. The comparison group was given a slideshow presentation with the same information. Participants viewed the 360-degree program or the slideshow presentation only once. The online-based materials consisted of a demographic form (age, gender, race and ethnicity, and name of school), knowledge questionnaires, and an experiential learning scale. Pre-intervention, participants were asked about demographic information, whether they had previous experience with MS, the science classes they completed in high school and college, and their knowledge of the human brain and MS pathophysiology. At both pre- and post-intervention, participants completed the Multiple Sclerosis Magnetic Resonance Imaging Knowledge Questionnaire (MSMRIKQ) and the Multiple Sclerosis Knowledge Questionnaire (MSKQ). At post-intervention, participants completed a lesson experiential questionnaire about their experience viewing either the 360-degree video or the slideshow presentation. Permission to use the three instruments was obtained from their respective copyright holders.

Начало: 01.07.2020 Край: 31.12.2026 Възраст: от 18 г.

United States Hunter College of City University of New York NCT07538063

Активно (без набиране) Фаза 2

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Breast Cancer

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.

Начало: 30.06.2020 Край: 01.12.2028 Възраст: от 18 г.

United States The Methodist Hospital Research Institute NCT03820141

Активно (без набиране)

Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication

1 Paravisceral Abdominal Aortic Aneurysm 2 Juxtarenal Abdominal Aortic Aneurysm 3 Pararenal Abdominal Aortic Aneurysm 4 Complex Abdominal Aortic Aneurysms

Prospective, multi-center, non-randomized study with consecutive, eligible subject enrollment at each site, for the evaluation of the ChEVAS System for Endovascular Repair of Complex Abdominal Aortic Aneurysms.

Начало: 29.06.2020 Край: 31.12.2026 Възраст: от 18 г.

United States Endologix NCT04252573

Активно (без набиране)

Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Heart Failure

The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the Barostim System.

Начало: 26.06.2020 Край: 01.06.2028

United States CVRx, Inc. NCT04502316

Активно (без набиране) Фаза 2

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Kidney Cancer Stage III Renal Cell Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8

This phase II trial studies how well lenvatinib and pembrolizumab before surgery work in treating patients with kidney cancer that has spread from its original site of growth to nearby tissues or lymph nodes but has not spread to other places in the body (non-metastatic). Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lenvatinib and pembrolizumab before surgery may kill more tumor cells.

Начало: 22.06.2020 Край: 11.12.2026 Възраст: от 18 г.

United States Emory University NCT04393350

Активно (без набиране)

A Longitudinal Study of COVID-19 Sequelae and Immunity

COVID-19

Background: COVID-19 is a disease caused by the SARS-CoV-2 virus. It infects the respiratory tract. Some people who get COVID-19 have only mild symptoms. But for others, infection leads to pneumonia, respiratory failure, and, in some cases, death. Researchers want to learn more about any effects that may persist after people recover from COVID-19. Objective: To learn about any long-term medical problems that people who have recovered from COVID-19 might have, and whether they develop an immune response to SARS-CoV-2 that provides protection against reinfection. Eligibility: People age 18 and older who have recovered from documented COVID-19 or were in close contact with someone who had COVID-19 but did not get the infection Design: Participants will be screened over 2 visits. During visit 1, they will answer questions about any symptoms they are having and will be tested for SARS-CoV-2 infection which will involve a nasal swab sample or other FDA approved test. If the test is negative, they will proceed to the second visit, which will include: Physical examination Medical history Mental health interview (which may be recorded if the participant agrees) Chest x-ray (for recovered COVID-19 participants only) Blood and urine tests Pregnancy test (if needed) Lung function test (for recovered COVID-19 participants only) 6-minute walk test (for recovered COVID-19 participants only) Questionnaires about their general and mental health Leukapheresis to collect white blood cells (optional). Participants will be put into 1 of 2 groups: the COVID-19 group or the close contact group. Participants will have study visits every 6 months for 3 years. They will repeat some of the screening tests. Participants in the COVID-19 group may have visits more often if they develop symptoms that suggest re-infection with SARS-CoV-2....

Начало: 17.06.2020 Край: 31.12.2027 Възраст: 18–120 г.

United States National Institute of Allergy and Infectious Diseases ( NCT04411147

Активно (без набиране) Фаза 3

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Axial Spondyloarthritis Ankylosing Spondylitis r-axSpa Nr-axSpa

The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).

Начало: 16.06.2020 Край: 07.08.2026 Възраст: от 18 г.

Belgium, Bulgaria, China +11 UCB Biopharma SRL NCT04436640

Активно (без набиране) Фаза 3

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Relapsed/Refractory Follicular Lymphoma Follicular Lymphoma Refractory Follicular Lymphoma

The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.

Начало: 11.06.2020 Край: 01.03.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +14 Epizyme, Inc. NCT04224493

Активно (без набиране) Фаза 1

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Neuroblastoma

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

Начало: 11.06.2020 Край: 01.08.2026 Възраст: 2–21 г. Лечение

Australia, Belgium, France +6 Eli Lilly and Company NCT04106219

Активно (без набиране)

Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer

Prostate Carcinoma

This study is being done to determine whether levels of prostate cancer derived extracellular vesicles from blood and urine specimens correlate with response to primary local treatment (surgery) in prostate cancer.

Начало: 10.06.2020 Край: 01.12.2026 Възраст: от 18 г.

United States Mayo Clinic NCT06326216

Активно (без набиране)

NCI COVID-19 in Cancer Patients, NCCAPS Study

COVID-19 Infection Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm

This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.

Начало: 05.06.2020 Край: 03.10.2026

Canada, Puerto Rico, United States National Cancer Institute (NCI) NCT04387656

Активно (без набиране) Фаза 1/2

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

Merkel Cell Carcinoma Basal Cell Carcinoma Locally Advanced Cutaneous Squamous Cell Carcinoma Cancer

The purpose of this study is to assess the safety and efficacy of RP1 (administered into the tumor) in 90 patients who have received an organ transplant in the past and currently have skin cancer. The skin cancer is either locally advanced (large tumors in the skin, muscles or nerves) or metastatic (spread to other parts of the body). This study will consist of a 28-day Screening Period, a Treatment Period, and a Follow-up Period. During the Treatment Period, patients will be dosed with RP1 every two weeks for up to 2 years (104 weeks). Tumor measurements will be done approximately every 8 weeks (and additionally if needed) until progressive disease, start of subsequent anticancer therapy, or completion/discontinuation of the study. During the Follow-up Period, patients will visit the clinic at 30, 60, and 100-150 days after their last dose of RP1 for safety and quality of life assessments. Patients will continue follow-up for up to 3 years from the day of the last patient's first dose.

Начало: 15.05.2020 Край: 01.11.2029 Възраст: от 18 г.

United States Replimune, Inc. NCT04349436

Активно (без набиране) Фаза 1

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Endometrial High Grade Endometrioid Adenocarcinoma Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube High Grade Serous Adenocarcinoma +25

This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a period of improvement (recurrent). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving peposertib and pegylated liposomal doxorubicin hydrochloride may work better in treating patients with ovarian cancer compared to pegylated liposomal doxorubicin hydrochloride alone.

Начало: 07.05.2020 Край: 01.06.2026 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT04092270

Активно (без набиране) Фаза 3

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Начало: 07.05.2020 Край: 30.06.2028 Възраст: от 18 г. Лечение

Australia, Belgium, China +10 GlaxoSmithKline NCT04246047

Активно (без набиране) Фаза 1/2

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Phase I: Relapsed or Refractory B-cell Malignancies Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia

This is an open-label, two-part study to assess the safety, tolerability, pharmacokinetics and clinical efficacy of acalabrutinib in Chinese adult subjects with R/R MCL, CLL and other B-cell malignancies. The study is divided into 2 parts: Phase 1 portion and Phase 2 portion.

Начало: 29.04.2020 Край: 24.06.2026 Възраст: 18–130 г.

China AstraZeneca NCT03932331

Активно (без набиране) Фаза 2

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Solid Tumor Medullary Thyroid Cancer

The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Начало: 16.03.2020 Край: 01.11.2027 Възраст: от 18 г.

China Eli Lilly and Company NCT04280081

1 … 225 226 227 228 229 … 240